Trust Co. of Vermont Purchases Shares of 28,800 CVS Health Corporation $CVS

Trust Co. of Vermont bought a new position in shares of CVS Health Corporation (NYSE:CVS) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 28,800 shares of the pharmacy operator’s stock, valued at approximately $2,979,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in CVS. Elevation Wealth Partners LLC lifted its position in shares of CVS Health by 41.8% during the 2nd quarter. Elevation Wealth Partners LLC now owns 356 shares of the pharmacy operator’s stock worth $37,000 after purchasing an additional 105 shares during the last quarter. Apella Capital LLC lifted its holdings in shares of CVS Health by 1.7% during the second quarter. Apella Capital LLC now owns 6,940 shares of the pharmacy operator’s stock worth $724,000 after buying an additional 117 shares during the last quarter. CYBER HORNET ETFs LLC lifted its holdings in shares of CVS Health by 4.1% during the third quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock worth $259,000 after buying an additional 134 shares during the last quarter. Northwestern Mutual Investment Management Company LLC boosted its position in shares of CVS Health by 0.3% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock valued at $3,219,000 after acquiring an additional 136 shares during the period. Finally, CoreCap Advisors LLC grew its stake in shares of CVS Health by 4.2% in the second quarter. CoreCap Advisors LLC now owns 3,481 shares of the pharmacy operator’s stock worth $360,000 after acquiring an additional 139 shares during the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other CVS Health news, Director Larry Robbins sold 370,462 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the sale, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This trade represents a 7.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.85% of the stock is currently owned by corporate insiders.

CVS Health Stock Performance

NYSE:CVS opened at $93.99 on Tuesday. The stock has a market capitalization of $120.21 billion, a P/E ratio of 24.87, a price-to-earnings-growth ratio of 0.93 and a beta of 0.61. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. CVS Health Corporation has a 1 year low of $69.40 and a 1 year high of $110.68. The firm has a 50 day moving average of $102.46 and a 200-day moving average of $88.41.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.71. The firm had revenue of $106.10 billion during the quarter, compared to the consensus estimate of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, sell-side analysts anticipate that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were given a dividend of $0.665 per share. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 annualized dividend and a yield of 2.8%. CVS Health’s dividend payout ratio is 70.37%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on CVS shares. HSBC reissued a “hold” rating and issued a $103.00 price target on shares of CVS Health in a report on Monday, July 6th. Royal Bank Of Canada lifted their target price on CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a research report on Thursday, July 9th. Cantor Fitzgerald upped their price target on CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. Barclays raised their price objective on CVS Health from $106.00 to $108.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Finally, Bank of America upped their target price on CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. Twenty-two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $106.75.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.